论文部分内容阅读
目的:探讨脑脉泰胶囊加复方脑蛋白水解物片治疗老年恢复期脑梗死的临床疗效。方法:72例老年恢复期脑梗死患者随机分为观察组和对照组各36例。两组均口服阿司匹林肠溶片抗血小板聚集,予以控制血糖、血压,调节血脂等基础治疗。对照组加用复方脑蛋白水解物片,口服,4片/次,3次/d;观察组在对照组基础上加服脑脉泰胶囊,口服,2粒/次,3次/d。两组疗程均为8周。采用简易智能状态检查修正表(MMSE)和日常生活能力量表(ADL)分别对两组的智能状态、日常生活能力进行评价。结果:治疗后观察组MMSE评分高于对照组(P<0.01),ADL评分低于对照组(P<0.05);观察组恢复期中风病疗效总有效率为83.33%优于对照组的61.11%(P<0.05);观察组中医证候疗效总有效率为91.67%优于对照组的66.67%(P<0.05)。结论:脑脉泰胶囊能明显改善脑梗死恢复期患者的认知功能和日常生活能力,对脑梗死恢复期患者神经功能有明显改善作用,并改善了临床症状,提高了疾病疗效。
Objective: To investigate the clinical curative effect of Naomaitai Capsule plus compound brain hydrolyzate tablet in the treatment of senile convalescent cerebral infarction. Methods: Seventy-two elderly patients with convalescent cerebral infarction were randomly divided into observation group (36 cases) and control group (36 cases). Both groups oral aspirin enteric-coated anti-platelet aggregation, to control blood sugar, blood pressure, blood lipid and other basic treatment. The control group was treated with compound brain hydrolysate tablets orally, 4 tablets / time, 3 times / d. The observation group was given Naoyitai capsule on the basis of the control group orally, 2 capsules / time, 3 times / d. The two groups were treated for 8 weeks. The MMSE and ADL were used to evaluate the intelligence status and daily living ability of the two groups respectively. Results: After treatment, MMSE score of the observation group was higher than that of the control group (P <0.01), and ADL score was lower than that of the control group (P0.05); the total effective rate of the curative effect of the stroke group was 83.33% (P <0.05). The total effective rate of TCM syndromes in observation group was 91.67%, which was higher than 66.67% of control group (P <0.05). Conclusion: Naomaitai Capsule can significantly improve cognitive function and daily living ability in patients with convalescent cerebral infarction, improve neurological function in patients with convalescent cerebral infarction, and improve clinical symptoms and improve the efficacy of the disease.